At a glance

ClinicalIndex Comparison Record

Phase 1Completed

Drug / intervention

topotecandrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00001333

NCT00001333Phase 1Completed

Compare CT.gov

Phase I Study of Intrathecal Topotecan

National Cancer Institute (NCI)·interventional·Posted Dec 10, 2002·Updated Mar 4, 2008

In Brief

A Phase 1 clinical trial evaluating topotecan for Leukemia and 2 related conditions. Completed, across 1 site.

Detailed Summary

The purpose of this study is to determine the qualitative and quantitative toxicity of intrathecal topotecan, a topoisomerase I inhibitor, in patients with meningeal malignancies refractory to conventional therapy (radiation therapy and chemotherapy).

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsLeukemia, Lymphoma, Meningeal Neoplasms

CountriesUnited States

Collaborators--

Timeline

Phase 1CompletedFinished

19931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartFeb 1993

Study CompletionDec 2000

First PostedDec 2002

TodayJul 2026

First PostedDec 10, 2002

Enrollment StartFeb 1, 1993

Study CompletionDec 1, 2000

TodayJul 2, 2026

Posted 23.6 years ago

Interventions

topotecandrug